Business Insider22h
Gilead price target raised to $100 from $85 at Argus
The company ecently announced that the FDA granted accelerated approval for Livdelzi in combination with ursodeoxycholic acidfor the treatment of primary biliary cholangitis, the analyst tells ...
clinicaltrialsarena1d
Gilead’s Livdelzi shows promise in PBC clinical trial
Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...
Gilead's Livdelzi Shows Sustained Efficacy, Long-Term Safety In PBC Management
Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which ...
The Pharma Letter3d
Gilead’s Livdelzi reduced pruritus severity in PBC participants
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...
Gilead to see Bay Area layoffs in wake of Seattle office closing
The global biopharmaceutical company stated in a California state filing this week it plans to cut 104 jobs at its offices at ...
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
Intercept loses Ocaliva FDA full approval bid in rare liver disease
Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...
US FDA declines full approval for Intercept's liver disease drug
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...
MedPage Today8d
FDA Rejects Full Approval of Liver Disease Drug
Notably, the FDA this year granted accelerated approval to two other drugs -- seladelpar (Livdelzi) and elafibranor (Iqirvo)- ...
Gilead Sciences: Approaching Overvalued
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
Hosted on MSN11d
Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript
We are very encouraged by the launch of Livdelzi for primary biliary cholangitis or PBC, which was granted accelerated approval by the FDA in August. Livdelzi is a highly differentiated option for ...